Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Jack Yanovski
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00001723CT.gov Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Sleep Apnea Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Orlistat (this asset) | Jack Yanovski | P2 | B · 57 |
| Trazodone | Chang Gung Memorial Hospital | P4 | BB |
| Valsartan | University Hospital, Grenoble | P4 | BB |
| Propofol | Icahn School of Medicine at Mount Sinai | P4 | BB |
| Amlodipine | University Hospital, Grenoble | P4 | BB |
| Dexmedetomidine | American University of Beirut Medical Center | P2/3 | B |
| Nepenthe | American University of Beirut Medical Center | P2/3 | B |
| Mazdutide | Innovent Biologics (Suzhou) Co. Ltd. | P3 | B |
| Montelukast | Great Ormond Street Hospital for Children NHS Foundation Trust | P2/3 | B |
+10 more in the Sleep Apnea Syndrome cohort
Other indications for Orlistat
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Type 2 Diabetes Mellitus | — | P4 | BBB · 73 |
| Polycystic Ovary Syndrome | — | P4 | BB · 70 |
| Binge Eating Disorder | — | P4 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Orlistat in Sleep Apnea Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/orlistat-sleep-apnea-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →